Katherine Hasal, MS

The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.

In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.

People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.

Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.

After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.

The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.

The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.

The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.

Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.

Cholestyramine and activated charcoal can be used to virtually eliminate the long half-life oral investigational multiple sclerosis drug, teriflunomide, from the plasma in 11 days.

People with MS frequently reported having both episodic and chronic migraines, with Hispanic MS patients experiencing significantly more chronic migraines.

In clinical trials, treatment of patients with the oral disease-modifying therapy, teriflunomide, for relapsing forms of multiple sclerosis can result in hair loss/thinning, but this side effect is generally manageable.